133 related articles for article (PubMed ID: 20370598)
1. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
Tengstrand EA; Miwa GT; Hsieh FY
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
[TBL] [Abstract][Full Text] [Related]
2. Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment.
Liu N; Tengstrand EA; Chourb L; Hsieh FY
Toxicol Appl Pharmacol; 2014 Sep; 279(3):467-476. PubMed ID: 24967688
[TBL] [Abstract][Full Text] [Related]
3. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers to monitor drug-induced phospholipidosis.
Baronas ET; Lee JW; Alden C; Hsieh FY
Toxicol Appl Pharmacol; 2007 Jan; 218(1):72-8. PubMed ID: 17156806
[TBL] [Abstract][Full Text] [Related]
5. A strategy for risk management of drug-induced phospholipidosis.
Chatman LA; Morton D; Johnson TO; Anway SD
Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
7. Bis(monoacylglycero)phosphate, a peculiar phospholipid to control the fate of cholesterol: Implications in pathology.
Hullin-Matsuda F; Luquain-Costaz C; Bouvier J; Delton-Vandenbroucke I
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):313-24. PubMed ID: 19857945
[TBL] [Abstract][Full Text] [Related]
8. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
9. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP.
Mesens N; Desmidt M; Verheyen GR; Starckx S; Damsch S; De Vries R; Verhemeldonck M; Van Gompel J; Lampo A; Lammens L
Toxicol Pathol; 2012 Apr; 40(3):491-503. PubMed ID: 22291062
[TBL] [Abstract][Full Text] [Related]
10. Phospholipidosis in nonclinical toxicity studies.
Berridge BR; Chatman LA; Odin M; Schultze AE; Losco PE; Meehan JT; Peters T; Vonderfecht SL;
Toxicol Pathol; 2007 Feb; 35(2):325. PubMed ID: 17366328
[No Abstract] [Full Text] [Related]
11. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
12. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
13. Cellular responses associated with dibucaine-induced phospholipidosis.
Peropadre A; Fernández Freire P; Herrero O; Pérez Martín JM; Hazen MJ
Chem Res Toxicol; 2011 Feb; 24(2):185-92. PubMed ID: 21261262
[TBL] [Abstract][Full Text] [Related]
14. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals.
Jiang Z; Reilly J
J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505
[TBL] [Abstract][Full Text] [Related]
15. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
16. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
17. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
[TBL] [Abstract][Full Text] [Related]
18. A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red.
Halstead BW; Zwickl CM; Morgan RE; Monteith DK; Thomas CE; Bowers RK; Berridge BR
J Appl Toxicol; 2006; 26(2):169-77. PubMed ID: 16278808
[TBL] [Abstract][Full Text] [Related]
19. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
20. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
